Phase 2A Dose and Route Study of a DNA Prime MVA Boost Vaccine Candidate. In AIDS Vaccine 2005 International Conference. presented at the 06/09/2005, Montreal, Quebec, Canada.. (2005).
Acceptability and Feasibility of Repeated Mucosal Specimen Collection in Clinical Trial Participants in Kenya. PLoS One, 9, e110228. presented at the 10/2014. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/25360819. (2014).
Baseline Morbidity in 2,990 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials. PLoS ONE, 3, e2043. presented at the 04/2008. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/18446196. (2008).
Safety and Immunogenicity Study of Multiclade HIV-1 Adeno-Viral Vector Vaccine Alone or as Boost Following a Multiclade HIV-1 DNA Vaccine in Africa. PLoS ONE, 5, e12873. presented at the 09/2010. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/20877623. (2010).
Studies of a Prophylactic HIV-1 Vaccine Candidate Based on Modified Vaccinia Virus Ankara (MVA) with and without DNA Priming: Effects of Dosage and Route on Safety and Immunogenicity. Vaccine, 25, 2120-2127. presented at the 03/2007. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/17250931. (2007).